Akums Drugs and Pharmaceuticals Ltd. on Monday reported a 4.3% year-on-year decline in adjusted net profit for the fourth quarter of FY25, even as revenue rose 12.4%, reflecting margin pressures and continued investment in capacity and R&D.
Adjusted PAT for Q4FY25 stood at ₹44 crore, down from ₹46 crore in Q4FY24. Revenue rose to ₹1,073 crore, while adjusted EBITDA grew 13.3% YoY to ₹111 crore, with margins holding at 10.4%.
For the full year FY25, total income rose 1% YoY to ₹4,170 crore, adjusted EBITDA was flat at ₹513 crore and margin rose slightly to 12.3%. Adjusted PAT grew 6.4% YoY to ₹234 crore.
The company attributed the flat annual revenue to muted industry volumes and API price erosion, though it maintained profitability through operational discipline and a focus on high-margin segments.
CDMO business which contributed 78% of revenue, with 14.1% EBITDA margin. Domestic branded formulations: rose 9% YoY, international branded formulations rose 14% YoY.
Trade generics & API continued to post operational losses.
Akums secured a €200 million contract to supply pharmaceutical products to regulated European markets, with commercial supplies beginning in 2027. The company invested ₹272 crore in capex and ₹130 crore in R&D during FY25, reinforcing its innovation-led growth strategy.
“Our entry into Europe is a pivotal step in our global CDMO expansion,” said Managing Director Sanjeev Jain. “We are laying the foundation for Akums to emerge as a trusted global CDMO.”
Co-MD Sandeep Jain added, “Despite industry volatility, we stayed focused on fundamentals—operational discipline, innovation, and global ambition.”
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
